SCHEMBL4293011

SCHEMBL4293011

CCCC[Sn](CCCC)(CCCC)c1nnn(Cc2ccccc2)c1CN1C(=O)c2ccccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
CASP3 P42574 1/20 0.42
IDO1 P14902 3/20 0.40
TDO2 P48775 2/20 0.40
TSHR P16473 1/20 0.39
PTK2B Q14289 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GABRA1 P14867 1/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
TYR P14679 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3671856 0.92 KDM4E (0.37) KDM4EALDH1A1HPGDRECQLCASP3
SCHEMBL4291497 0.82 GRM2 (0.39) KDM4EALDH1A1HPGDIDO1MEN1
SCHEMBL4292592 0.77 GRM2 (0.41) KDM4EALDH1A1HPGDIDO1TSHR
SCHEMBL4292554 0.76 CDC7 (0.44) HPGDIDO1TDO2
SCHEMBL4289574 0.76 CDC7 (0.45) KDM4E
SCHEMBL3669940 0.75 CYP19A1 (0.48) ALDH1A1IDO1TDO2TSHR
SCHEMBL4284874 0.75 CDC7 (0.46) KDM4E
SCHEMBL3667322 0.72 ROCK2 (0.43) KDM4EALDH1A1HPGDIDO1
SCHEMBL4291234 0.72 SMN1; SMN2 (0.51) ALDH1A1HPGDTSHRMEN1KMT2A
SCHEMBL4295553 0.70 CDC7 (0.46) IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9163007-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2015-10-20 US disclosed
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS AbbVie Deutschland GmbH & Co. KG (DE) 2014-11-20 US disclosed
US-8648069-B2 5-substituted indazoles as kinase inhibitors ABBVIE INC. (US) 2014-02-11 US disclosed
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343066-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 KDM4E 1238/4885ALDH1A1 2761/4885HPGD 3592/4885
US-20090203690-A1 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS GSK3B, GSK3A, PIM3 KDM4E 1238/4885ALDH1A1 2761/4885HPGD 3592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.